title: Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer.
abstract: CONCLUSIONS
  Nedaplatin and S-1 treatment with concurrent radiotherapy was effective, with acceptable toxicities. This regimen does not require extensive intravenous hydration and continuous infusion. Nedaplatin and S-1 may contribute to better clinical outcomes and improve quality of life for patients.
  
  
  OBJECTIVE
  We retrospectively analyzed the clinical efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell cancer.
  
  
  METHODS
  Forty-six patients with oropharyngeal, hypopharyngeal, and laryngeal cancer were treated with S-1 on days 1 through 14 and nedaplatin on day 1 every 4 weeks for two cycles of radiotherapy. Therapeutic responses and adverse events were assessed.
  
  
  RESULTS
  Primary site tumors and neck lymph nodes exhibited complete response rates of 91% and 64.3%, respectively. The 4-year relapse-free survival and overall survival rates were 76.2% and 85.3%, respectively. The main grade 3 and 4 toxicities were mucositis (30%), leukopenia (30%), anorexia (22%), dermatitis (15%), and thrombocytopenia (9%).
authors.affiliation: Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kagawa , Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hoshikawa
authors.forename: Takehito
authors.initials: T
authors.lastname: Kishino
authors.forename: Terushige
authors.initials: T
authors.lastname: Mori
authors.forename: Kanako
authors.initials: K
authors.lastname: Indo
authors.forename: Ryuhei
authors.initials: R
authors.lastname: Inamoto
authors.forename: Kosuke
authors.initials: K
authors.lastname: Akiyama
authors.forename: Takenori
authors.initials: T
authors.lastname: Miyashita
authors.forename: Nozomu
authors.initials: N
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010094:Oxonic Acid / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D005641:Tegafur / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D009944:Organoplatinum Compounds; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; C053989:nedaplatin
keywords: CDGP; S-1; chemoradiation; survival